David Lodge - Publications

Affiliations: 
University of Bristol, Bristol, England, United Kingdom 

92 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Frenguelli B, Lodge D, Rammes G, Collingridge G, Quack G, Jerecic J, Headley M, Danysz W. A tribute to Chris Parsons. Neuropharmacology. 195: 108633. PMID 34198024 DOI: 10.1016/j.neuropharm.2021.108633  0.338
2020 Kang H, Park P, Han M, Tidball P, Georgiou J, Bortolotto ZA, Lodge D, Kaang BK, Collingridge GL. (2,6)- and (2,6)-hydroxynorketamine inhibit the induction of NMDA receptor-dependent LTP at hippocampal CA1 synapses in mice. Brain and Neuroscience Advances. 4: 2398212820957847. PMID 33088919 DOI: 10.1177/2398212820957847  0.832
2019 Wallach J, Colestock T, Agramunt J, Claydon MDB, Dybek M, Filemban N, Chatha M, Halberstadt AL, Brandt SD, Lodge D, Bortolotto ZA, Adejare A. Pharmacological characterizations of the legal high fluorolintane and isomers. European Journal of Pharmacology. 172427. PMID 31152702 DOI: 10.1016/J.Ejphar.2019.172427  0.761
2018 Lodge D, Watkins JC, Bortolotto ZA, Jane DE, Volianskis A. The 1980s: D-AP5, LTP and a Decade of NMDA Receptor Discoveries. Neurochemical Research. PMID 30284673 DOI: 10.1007/S11064-018-2640-6  0.796
2018 Wood CM, Wafford KA, McCarthy AP, Hewes N, Shanks E, Lodge D, Robinson ES. Investigating the role of mGluR2 versus mGluR3 in antipsychotic-like effects, sleep-wake architecture and network oscillatory activity using novel Han Wistar rats lacking mGluR2 expression. Neuropharmacology. PMID 30005976 DOI: 10.1016/j.neuropharm.2018.07.013  0.374
2018 Ingram R, Kang H, Lightman S, Jane DE, Bortolotto ZA, Collingridge GL, Lodge D, Volianskis A. Some distorted thoughts about ketamine as a psychedelic and a novel hypothesis based on NMDA receptor-mediated synaptic plasticity. Neuropharmacology. PMID 29885421 DOI: 10.1016/J.Neuropharm.2018.06.008  0.82
2017 Mastroiacovo F, Moyanova S, Cannella M, Gaglione A, Verhaeghe R, Bozza G, Madonna M, Motolese M, Traficante A, Riozzi B, Bruno V, Battaglia G, Lodge D, Nicoletti F. Genetic deletion of mGlu2 metabotropic glutamate receptors improves the short-term outcome of cerebral transient focal ischemia. Molecular Brain. 10: 39. PMID 28821279 DOI: 10.1186/s13041-017-0319-6  0.514
2016 Collingridge GL, Lee Y, Bortolotto ZA, Kang H, Lodge D. Antidepressant Actions of Ketamine Versus Hydroxynorketamine. Biological Psychiatry. PMID 27817845 DOI: 10.1016/j.biopsych.2016.06.029  0.658
2016 Collingridge GL, Lodge D, Mayer M, Turrigiano G, Frenguelli BG. Ionotropic glutamate receptors: still exciting after all these years. Neuropharmacology. PMID 27659748 DOI: 10.1016/J.Neuropharm.2016.09.019  0.665
2016 Kang H, Park P, Bortolotto ZA, Brandt SD, Colestock T, Wallach J, Collingridge GL, Lodge D. Ephenidine: A new psychoactive agent with ketamine-like NMDA receptor antagonist properties. Neuropharmacology. PMID 27520396 DOI: 10.1016/j.neuropharm.2016.08.004  0.816
2016 Wallach J, Kang H, Colestock T, Morris H, Bortolotto ZA, Collingridge GL, Lodge D, Halberstadt AL, Brandt SD, Adejare A. Pharmacological Investigations of the Dissociative 'Legal Highs' Diphenidine, Methoxphenidine and Analogues. Plos One. 11: e0157021. PMID 27314670 DOI: 10.1371/Journal.Pone.0157021  0.733
2016 Wood CM, Nicolas CS, Choi SL, Roman E, Nylander I, Fernandez-Teruel A, Kiianmaa K, Bienkowski P, de Jong TR, Colombo G, Chastagnier D, Wafford KA, Collingridge GL, Wildt SJ, Conway-Campbell BL, ... ... Lodge D, et al. Prevalence and influence of cys407* Grm2 mutation in Hannover-derived Wistar rats: mGlu2 receptor loss links to alcohol intake, risk taking and emotional behaviour. Neuropharmacology. PMID 26987983 DOI: 10.1016/j.neuropharm.2016.03.020  0.656
2015 Wallis JL, Irvine MW, Jane DE, Lodge D, Collingridge GL, Bortolotto ZA. An interchangeable role for kainate and metabotropic glutamate receptors in the induction of rat hippocampal mossy fiber long-term potentiation in vivo. Hippocampus. PMID 25821051 DOI: 10.1002/Hipo.22460  0.833
2015 Wallach J, Kavanagh PV, McLaughlin G, Morris N, Power JD, Elliott SP, Mercier MS, Lodge D, Morris H, Dempster NM, Brandt SD. Preparation and characterization of the 'research chemical' diphenidine, its pyrrolidine analogue, and their 2,2-diphenylethyl isomers. Drug Testing and Analysis. 7: 358-67. PMID 25044512 DOI: 10.1002/dta.1689  0.351
2014 Mercier MS, Lodge D. Group III metabotropic glutamate receptors: pharmacology, physiology and therapeutic potential. Neurochemical Research. 39: 1876-94. PMID 25146900 DOI: 10.1007/s11064-014-1415-y  0.601
2013 Lodge D, Tidball P, Mercier MS, Lucas SJ, Hanna L, Ceolin L, Kritikos M, Fitzjohn SM, Sherwood JL, Bannister N, Volianskis A, Jane DE, Bortolotto ZA, Collingridge GL. Antagonists reversibly reverse chemical LTD induced by group I, group II and group III metabotropic glutamate receptors. Neuropharmacology. 74: 135-46. PMID 23542080 DOI: 10.1016/J.Neuropharm.2013.03.011  0.808
2013 Crabtree JW, Lodge D, Bashir ZI, Isaac JT. GABAA , NMDA and mGlu2 receptors tonically regulate inhibition and excitation in the thalamic reticular nucleus. The European Journal of Neuroscience. 37: 850-9. PMID 23294136 DOI: 10.1111/ejn.12098  0.665
2013 Mercier MS, Lodge D, Fang G, Nicolas CS, Collett VJ, Jane DE, Collingridge GL, Bortolotto ZA. Characterisation of an mGlu8 receptor-selective agonist and antagonist in the lateral and medial perforant path inputs to the dentate gyrus. Neuropharmacology. 67: 294-303. PMID 23220400 DOI: 10.1016/J.Neuropharm.2012.11.020  0.806
2013 Collingridge GL, Volianskis A, Bannister N, France G, Hanna L, Mercier M, Tidball P, Fang G, Irvine MW, Costa BM, Monaghan DT, Bortolotto ZA, Molnár E, Lodge D, Jane DE. The NMDA receptor as a target for cognitive enhancement. Neuropharmacology. 64: 13-26. PMID 22796429 DOI: 10.1016/J.Neuropharm.2012.06.051  0.798
2013 Sanger H, Hanna L, Colvin EM, Grubisha O, Ursu D, Heinz BA, Findlay JD, Vivier RG, Sher E, Lodge D, Monn JA, Broad LM. Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR. Neuropharmacology. 66: 264-73. PMID 22659090 DOI: 10.1016/j.neuropharm.2012.05.023  0.568
2013 Lucas SJ, Bortolotto ZA, Collingridge GL, Lodge D. Selective activation of either mGlu2 or mGlu3 receptors can induce LTD in the amygdala. Neuropharmacology. 66: 196-201. PMID 22531751 DOI: 10.1016/j.neuropharm.2012.04.006  0.827
2013 Hanna L, Ceolin L, Lucas S, Monn J, Johnson B, Collingridge G, Bortolotto Z, Lodge D. Differentiating the roles of mGlu2 and mGlu3 receptors using LY541850, an mGlu2 agonist/mGlu3 antagonist. Neuropharmacology. 66: 114-21. PMID 22445601 DOI: 10.1016/j.neuropharm.2012.02.023  0.811
2012 Sherwood JL, Amici M, Dargan SL, Culley GR, Fitzjohn SM, Jane DE, Collingridge GL, Lodge D, Bortolotto ZA. Differences in kainate receptor involvement in hippocampal mossy fibre long-term potentiation depending on slice orientation. Neurochemistry International. 61: 482-9. PMID 22564530 DOI: 10.1016/J.Neuint.2012.04.021  0.842
2012 Ceolin L, Bortolotto ZA, Bannister N, Collingridge GL, Lodge D, Volianskis A. A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochemistry International. 61: 517-22. PMID 22433907 DOI: 10.1016/j.neuint.2012.02.035  0.803
2012 Lodge DJ, Grace AA. Gestational methylazoxymethanol acetate administration alters proteomic and metabolomic markers of hippocampal glutamatergic transmission. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 37: 319-20. PMID 22157947 DOI: 10.1038/npp.2011.255  0.307
2011 Ceolin L, Kantamneni S, Barker GR, Hanna L, Murray L, Warburton EC, Robinson ES, Monn JA, Fitzjohn SM, Collingridge GL, Bortolotto ZA, Lodge D. Study of novel selective mGlu2 agonist in the temporo-ammonic input to CA1 neurons reveals reduced mGlu2 receptor expression in a Wistar substrain with an anxiety-like phenotype. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 6721-31. PMID 21543601 DOI: 10.1523/JNEUROSCI.0418-11.2011  0.855
2010 Huang LT, Sherwood JL, Sun YJ, Lodge D, Wang Y. Activation of presynaptic alpha7 nicotinic receptors evokes an excitatory response in hippocampal CA3 neurones in anaesthetized rats: an in vivo iontophoretic study. British Journal of Pharmacology. 159: 554-65. PMID 20105181 DOI: 10.1111/j.1476-5381.2009.00529.x  0.747
2009 Nisticò R, Dargan S, Fitzjohn SM, Lodge D, Jane DE, Collingridge GL, Bortolotto ZA. GLUK1 receptor antagonists and hippocampal mossy fiber function. International Review of Neurobiology. 85: 13-27. PMID 19607958 DOI: 10.1016/S0074-7742(09)85002-2  0.86
2009 Jane DE, Lodge D, Collingridge GL. Kainate receptors: pharmacology, function and therapeutic potential. Neuropharmacology. 56: 90-113. PMID 18793656 DOI: 10.1016/J.Neuropharm.2008.08.023  0.709
2009 Dargan SL, Clarke VR, Alushin GM, Sherwood JL, Nisticò R, Bortolotto ZA, Ogden AM, Bleakman D, Doherty AJ, Lodge D, Mayer ML, Fitzjohn SM, Jane DE, Collingridge GL. ACET is a highly potent and specific kainate receptor antagonist: characterisation and effects on hippocampal mossy fibre function. Neuropharmacology. 56: 121-30. PMID 18789344 DOI: 10.1016/J.Neuropharm.2008.08.016  0.846
2009 Lodge D. The history of the pharmacology and cloning of ionotropic glutamate receptors and the development of idiosyncratic nomenclature. Neuropharmacology. 56: 6-21. PMID 18765242 DOI: 10.1016/j.neuropharm.2008.08.006  0.635
2007 Bartlett TE, Bannister NJ, Collett VJ, Dargan SL, Massey PV, Bortolotto ZA, Fitzjohn SM, Bashir ZI, Collingridge GL, Lodge D. Differential roles of NR2A and NR2B-containing NMDA receptors in LTP and LTD in the CA1 region of two-week old rat hippocampus. Neuropharmacology. 52: 60-70. PMID 16904707 DOI: 10.1016/J.Neuropharm.2006.07.013  0.868
2006 Wang Y, Sherwood JL, Lodge D. The alpha4beta2 nicotinic acetylcholine receptor agonist TC-2559 impairs long-term potentiation in the dentate gyrus in vivo. Neuroscience Letters. 406: 183-8. PMID 16935422 DOI: 10.1016/j.neulet.2006.06.075  0.759
2006 Wang Y, Sherwood JL, Miles CP, Whiffin G, Lodge D. TC-2559 excites dopaminergic neurones in the ventral tegmental area by stimulating alpha4beta2-like nicotinic acetylcholine receptors in anaesthetised rats. British Journal of Pharmacology. 147: 379-90. PMID 16402043 DOI: 10.1038/sj.bjp.0706621  0.675
2006 Takeuchi K, Kohn TJ, Honigschmidt NA, Rocco VP, Spinazze PG, Hemrick-Luecke SK, Thompson LK, Evans DC, Rasmussen K, Koger D, Lodge D, Martin LJ, Shaw J, Threlkeld PG, Wong DT. Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 5. Bioorganic & Medicinal Chemistry Letters. 16: 2347-51. PMID 16298130 DOI: 10.1016/j.bmcl.2005.11.007  0.392
2004 Smolders I, Lindekens H, Clinckers R, Meurs A, O'Neill MJ, Lodge D, Ebinger G, Michotte Y. In vivo modulation of extracellular hippocampal glutamate and GABA levels and limbic seizures by group I and II metabotropic glutamate receptor ligands. Journal of Neurochemistry. 88: 1068-77. PMID 15009663 DOI: 10.1046/j.1471-4159.2003.02251.x  0.494
2003 Lodge DJ, Roques BP, Lawrence AJ. Atypical behavioural responses to CCK-B receptor ligands in Fawn-Hooded rats. Life Sciences. 74: 1-12. PMID 14575808 DOI: 10.1016/j.lfs.2003.03.003  0.362
2003 Lauri SE, Bortolotto ZA, Nistico R, Bleakman D, Ornstein PL, Lodge D, Isaac JT, Collingridge GL. A role for Ca2+ stores in kainate receptor-dependent synaptic facilitation and LTP at mossy fiber synapses in the hippocampus. Neuron. 39: 327-41. PMID 12873388 DOI: 10.1016/S0896-6273(03)00369-6  0.819
2003 Murray TK, Whalley K, Robinson CS, Ward MA, Hicks CA, Lodge D, Vandergriff JL, Baumbarger P, Siuda E, Gates M, Ogden AM, Skolnick P, Zimmerman DM, Nisenbaum ES, Bleakman D, et al. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. 306: 752-62. PMID 12730350 DOI: 10.1124/Jpet.103.049445  0.477
2002 Smolders I, Bortolotto ZA, Clarke VR, Warre R, Khan GM, O'Neill MJ, Ornstein PL, Bleakman D, Ogden A, Weiss B, Stables JP, Ho KH, Ebinger G, Collingridge GL, Lodge D, et al. Antagonists of GLU(K5)-containing kainate receptors prevent pilocarpine-induced limbic seizures. Nature Neuroscience. 5: 796-804. PMID 12080343 DOI: 10.1038/Nn880  0.759
2002 Sharpe EF, Kingston AE, Lodge D, Monn JA, Headley PM. Systemic pre-treatment with a group II mGlu agonist, LY379268, reduces hyperalgesia in vivo. British Journal of Pharmacology. 135: 1255-62. PMID 11877334 DOI: 10.1038/sj.bjp.0704583  0.314
2001 Lauri SE, Bortolotto ZA, Bleakman D, Ornstein PL, Lodge D, Isaac JT, Collingridge GL. A critical role of a facilitatory presynaptic kainate receptor in mossy fiber LTP. Neuron. 32: 697-709. PMID 11719209 DOI: 10.1016/S0896-6273(01)00511-6  0.83
2001 Vandergriff J, Huff K, Bond A, Lodge D. Potentiation of responses to AMPA on central neurones by LY392098 and LY404187 in vivo. Neuropharmacology. 40: 1003-9. PMID 11406191 DOI: 10.1016/S0028-3908(01)00031-4  0.447
2001 Bortolotto ZA, Clarke VRJ, Delany CM, Parry MC, Smolders I, Vignes M, Ho KH, Miu P, Brinton BT, Fantaske R, Ogden A, Gates M, Ornstein PL, Lodge D, Bleakman D, et al. Erratum: correction: Kainate receptors are involved in synaptic plasticity Nature. 409: 542-542. DOI: 10.1038/35054109  0.8
2000 Doherty AJ, Palmer MJ, Bortolotto ZA, Hargreaves A, Kingston AE, Ornstein PL, Schoepp DD, Lodge D, Collingridge GL. A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices. British Journal of Pharmacology. 131: 239-44. PMID 10991916 DOI: 10.1038/Sj.Bjp.0703574  0.814
1999 Kingston AE, O'Neill MJ, Bond A, Bruno V, Battaglia G, Nicoletti F, Harris JR, Clark BP, Monn JA, Lodge D, Schoepp DD. Neuroprotective actions of novel and potent ligands of group I and group II metabotropic glutamate receptors. Annals of the New York Academy of Sciences. 890: 438-49. PMID 10668448 DOI: 10.1111/j.1749-6632.1999.tb08022.x  0.474
1999 Bortolotto ZA, Clarke VR, Delany CM, Parry MC, Smolders I, Vignes M, Ho KH, Miu P, Brinton BT, Fantaske R, Ogden A, Gates M, Ornstein PL, Lodge D, Bleakman D, et al. Kainate receptors are involved in synaptic plasticity. Nature. 402: 297-301. PMID 10580501 DOI: 10.1038/46290  0.822
1999 Fitzjohn SM, Kingston AE, Lodge D, Collingridge GL. DHPG-induced LTD in area CA1 of juvenile rat hippocampus; characterisation and sensitivity to novel mGlu receptor antagonists. Neuropharmacology. 38: 1577-83. PMID 10530819 DOI: 10.1016/S0028-3908(99)00123-9  0.847
1999 Cushing A, Price-Jones MJ, Graves R, Harris AJ, Hughes KT, Bleakman D, Lodge D. Measurement of calcium flux through ionotropic glutamate receptors using Cytostar-T scintillating microplates. Journal of Neuroscience Methods. 90: 33-6. PMID 10517271 DOI: 10.1016/S0165-0270(99)00058-8  0.455
1999 Bond A, Ragumoorthy N, Monn JA, Hicks CA, Ward MA, Lodge D, O'Neill MJ. LY379268, a potent and selective Group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischaemia. Neuroscience Letters. 273: 191-4. PMID 10515191 DOI: 10.1016/S0304-3940(99)00663-1  0.323
1999 Bond A, Lodge D, Hicks CA, Ward MA, O'Neill MJ. NMDA receptor antagonism, but not AMPA receptor antagonism attenuates induced ischaemic tolerance in the gerbil hippocampus. European Journal of Pharmacology. 380: 91-9. PMID 10513567 DOI: 10.1016/S0014-2999(99)00523-3  0.474
1998 Fitzjohn SM, Bortolotto ZA, Palmer MJ, Doherty AJ, Ornstein PL, Schoepp DD, Kingston AE, Lodge D, Collingridge GL. The potent mGlu receptor antagonist LY341495 identifies roles for both cloned and novel mGlu receptors in hippocampal synaptic plasticity. Neuropharmacology. 37: 1445-58. PMID 9886667 DOI: 10.1016/S0028-3908(98)00145-2  0.874
1998 Ornstein PL, Arnold MB, Lunn WH, Heinz LJ, Leander JD, Lodge D, Schoepp DD. Heteroatom-substitution as a strategy for increasing the potency of competitive NMDA antagonists. Bioorganic & Medicinal Chemistry Letters. 8: 389-94. PMID 9871691 DOI: 10.1016/S0960-894X(98)00038-9  0.509
1998 Procter MJ, Houghton AK, Faber ES, Chizh BA, Ornstein PL, Lodge D, Headley PM. Actions of kainate and AMPA selective glutamate receptor ligands on nociceptive processing in the spinal cord. Neuropharmacology. 37: 1287-97. PMID 9849666 DOI: 10.1016/S0028-3908(98)00136-1  0.438
1998 Vignes M, Clarke VR, Parry MJ, Bleakman D, Lodge D, Ornstein PL, Collingridge GL. The GluR5 subtype of kainate receptor regulates excitatory synaptic transmission in areas CA1 and CA3 of the rat hippocampus. Neuropharmacology. 37: 1269-77. PMID 9849664 DOI: 10.1016/S0028-3908(98)00148-8  0.679
1998 O'Neill MJ, Bond A, Ornstein PL, Ward MA, Hicks CA, Hoo K, Bleakman D, Lodge D. Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia. Neuropharmacology. 37: 1211-22. PMID 9849659 DOI: 10.1016/S0028-3908(98)00134-8  0.504
1998 Bond A, O'Neill MJ, Hicks CA, Monn JA, Lodge D. Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia. Neuroreport. 9: 1191-3. PMID 9601692 DOI: 10.1097/00001756-199804200-00042  0.447
1998 Collingridge GL, Lodge D. 7th Neuropharmacology Conference: Editorial Neuropharmacology. 37: 1185. DOI: 10.1016/S0028-3908(98)00169-5  0.341
1997 Vignes M, Bleakman D, Lodge D, Collingridge GL. The synaptic activation of the GluR5 subtype of kainate receptor in area CA3 of the rat hippocampus. Neuropharmacology. 36: 1477-81. PMID 9517417 DOI: 10.1016/S0028-3908(97)00158-5  0.733
1997 Clarke VR, Ballyk BA, Hoo KH, Mandelzys A, Pellizzari A, Bath CP, Thomas J, Sharpe EF, Davies CH, Ornstein PL, Schoepp DD, Kamboj RK, Collingridge GL, Lodge D, Bleakman D. A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature. 389: 599-603. PMID 9335499 DOI: 10.1038/39315  0.701
1997 Bond A, Monn JA, Lodge D. A novel orally active group 2 metabotropic glutamate receptor agonist: LY354740. Neuroreport. 8: 1463-6. PMID 9172154 DOI: 10.1097/00001756-199704140-00027  0.48
1997 Willis CL, Wacker DA, Bartlett RD, Bleakman D, Lodge D, Chamberlin AR, Bridges RJ. Irreversible inhibition of high-affinity [3H]kainate binding by a novel photoactivatable analogue: (2'S,3'S,4'R)-2'-carboxy-4'-(2-diazo-1-oxo-3, 3,3-trifluoropropyl)-3'-pyrrolidinyl acetate. Journal of Neurochemistry. 68: 1503-10. PMID 9084420 DOI: 10.1046/J.1471-4159.1997.68041503.X  0.318
1996 Bleakman D, Ballyk BA, Schoepp DD, Palmer AJ, Bath CP, Sharpe EF, Woolley ML, Bufton HR, Kamboj RK, Tarnawa I, Lodge D. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles. Neuropharmacology. 35: 1689-702. PMID 9076748 DOI: 10.1016/S0028-3908(96)00156-6  0.516
1996 Lodge D, Bond A, O'Neill MJ, Hicks CA, Jones MG. Stereoselective effects-of 2,3-benzodiazepines in vivo: electrophysiology and neuroprotection studies. Neuropharmacology. 35: 1681-8. PMID 9076747 DOI: 10.1016/S0028-3908(96)00155-4  0.335
1996 Fletcher EJ, Lodge D. New developments in the molecular pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate and kainate receptors. Pharmacology & Therapeutics. 70: 65-89. PMID 8804111 DOI: 10.1016/0163-7258(96)00014-9  0.514
1996 Fitzjohn SM, Irving AJ, Palmer MJ, Harvey J, Lodge D, Collingridge GL. Activation of group I mGluRs potentiates NMDA responses in rat hippocampal slices. Neuroscience Letters. 203: 211-3. PMID 8742030 DOI: 10.1016/0304-3940(96)12301-6  0.787
1996 Ornstein PL, Arnold MB, Allen NK, Bleisch T, Borromeo PS, Lugar CW, Leander JD, Lodge D, Schoepp DD. Structure-activity studies of 6-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 2. Effects of distal acid bioisosteric substitution, absolute stereochemical preferences, and in vivo activity. Journal of Medicinal Chemistry. 39: 2232-44. PMID 8667366 DOI: 10.1021/jm950913h  0.321
1996 Ornstein PL, Arnold MB, Allen NK, Bleisch T, Borromeo PS, Lugar CW, Leander JD, Lodge D, Schoepp DD. Structure-activity studies of 6-(tetrazolylalkyl)-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 1. Effects of stereochemistry, chain length, and chain substitution. Journal of Medicinal Chemistry. 39: 2219-31. PMID 8667365 DOI: 10.1021/jm950912p  0.345
1996 Fitzjohn SM, Lodge D, Collingridge GL. Long-term depression of synaptic transmission induced by group in metabotropic glutamate receptor activation in the CA1 of young rat hippocampus Journal of Physiology Paris. 90: 410-4111. DOI: 10.1016/S0928-4257(97)87937-5  0.817
1996 Lodge D, Bond A. Spinal glutamate receptors Pharmacochemistry Library. 24: 241-252. DOI: 10.1016/S0165-7208(96)80020-1  0.338
1996 Lodge D, Monn JA, Bond A, Woolley ML. Interaction between metabotropic and ionotropic glutamate receptors on rat spinal cord in vivo and in vitro Neuropharmacology. 35: A18. DOI: 10.1016/0028-3908(96)84717-4  0.301
1995 Schoepp DD, Lodge D, Bleakman D, Leander JD, Tizzano JP, Wright RA, Palmer AJ, Salhoff CR, Ornstein PL. In vitro and in vivo antagonism of AMPA receptor activation by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl) ethyl] decahydroisoquinoline-3-carboxylic acid. Neuropharmacology. 34: 1159-68. PMID 8532186 DOI: 10.1016/0028-3908(95)00099-R  0.41
1995 Ornstein PL, Arnold MB, Allen NK, Leander JD, Tizzano JP, Lodge D, Schoepp DD. (3SR,4aRS,6SR,8aRS)-6-(1H-tetrazol-5-yl)decahydroisoquinoline-3-carboxylic acid, a novel, competitive, systemically active NMDA and AMPA receptor antagonist. Journal of Medicinal Chemistry. 38: 4885-90. PMID 8523401  0.475
1995 Collingridge G, Lodge D. Editorial Neuropharmacology. 34: v.  0.339
1993 Ornstein PL, Arnold MB, Augenstein NK, Lodge D, Leander JD, Schoepp DD. (3SR,4aRS,6RS,8aRS)-6-[2-(1H-tetrazol-5-yl)ethyl]decahydroisoquinoline-3 - carboxylic acid: a structurally novel, systemically active, competitive AMPA receptor antagonist. Journal of Medicinal Chemistry. 36: 2046-8. PMID 8393116  0.319
1993 Parsons CG, Gruner R, Rozental J, Millar J, Lodge D. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology. 32: 1337-50. PMID 8152525 DOI: 10.1016/0028-3908(93)90029-3  0.412
1993 Lodge D, Bond A. Pharmacology of ionotropic and metabotropic glutamate receptors European Neuropsychopharmacology. 3: 181-182. DOI: 10.1016/0924-977X(93)90013-C  0.509
1992 Ornstein PL, Schoepp DD, Arnold MB, Augenstein NK, Lodge D, Millar JD, Chambers J, Campbell J, Paschal JW, Zimmerman DM. 6-substituted decahydroisoquinoline-3-carboxylic acids as potent and selective conformationally constrained NMDA receptor antagonists. Journal of Medicinal Chemistry. 35: 3547-60. PMID 1404235  0.413
1992 Ornstein PL, Schoepp DD, Arnold MB, Jones ND, Deeter JB, Lodge D, Leander JD. NMDA antagonist activity of (+/-)-(2SR,4RS)-4-(1H-tetrazol-5-ylmethyl)piperidine-2-carboxylic acid resides with the (-)-2R,4S-isomer. Journal of Medicinal Chemistry. 35: 3111-5. PMID 1387167 DOI: 10.1021/Jm00095A004  0.324
1992 McQuaid LA, Smith EC, South KK, Mitch CH, Schoepp DD, True RA, Calligaro DO, O'Malley PJ, Lodge D, Ornstein PL. Synthesis and excitatory amino acid pharmacology of a series of heterocyclic-fused quinoxalinones and quinazolinones. Journal of Medicinal Chemistry. 35: 3319-24. PMID 1382133 DOI: 10.1021/Jm00096A002  0.388
1992 McQuaid LA, Smith EC, Lodge D, Pralong E, Wikel JH, Calligaro DO, O'Malley PJ. 3-Phenyl-4-hydroxyquinolin-2(1H)-ones: potent and selective antagonists at the strychnine-insensitive glycine site on the N-methyl-D-aspartate receptor complex. Journal of Medicinal Chemistry. 35: 3423-5. PMID 1326635 DOI: 10.1021/Jm00096A019  0.343
1991 Ornstein PL, Schoepp DD, Arnold MB, Leander JD, Lodge D, Paschal JW, Elzey T. 4-(Tetrazolylalkyl)piperidine-2-carboxylic acids. Potent and selective N-methyl-D-aspartic acid receptor antagonists with a short duration of action. Journal of Medicinal Chemistry. 34: 90-7. PMID 1825117 DOI: 10.1021/Jm00105A016  0.422
1990 Lodge D, Johnson KM. Noncompetitive excitatory amino acid receptor antagonists. Trends in Pharmacological Sciences. 11: 81-6. PMID 2156365 DOI: 10.1016/0165-6147(90)90323-Z  0.55
1990 Lodge D, Collingridge G. Les agents provocateurs: a series on the pharmacology of excitatory amino acids. Trends in Pharmacological Sciences. 11: 22-4. PMID 2155494 DOI: 10.1016/0165-6147(90)90037-9  0.497
1990 Ornstein PL, Schoepp DD, Leander JD, Wong T, Zimmerman DM, Lodge D. LY233053: a structurally novel, potent and selective competitive N-methyl-D-aspartate receptor antagonist. Progress in Clinical and Biological Research. 361: 429-33. PMID 2149764  0.373
1990 Schoepp DD, Ornstein PL, Leander JD, Lodge D, Salhoff CR, Zeman S, Zimmerman DM. Pharmacological characterization of LY233053: a structurally novel tetrazole-substituted competitive N-methyl-D-aspartic acid antagonist with a short duration of action. The Journal of Pharmacology and Experimental Therapeutics. 255: 1301-8. PMID 2148188  0.429
1988 Lodge D, Davies SN, Jones MG, Millar J, Manallack DT, Ornstein PL, Verberne AJ, Young N, Beart PM. A comparison between the in vivo and in vitro activity of five potent and competitive NMDA antagonists. British Journal of Pharmacology. 95: 957-65. PMID 2905186 DOI: 10.1111/J.1476-5381.1988.Tb11726.X  0.396
1988 Honoré T, Davies SN, Drejer J, Fletcher EJ, Jacobsen P, Lodge D, Nielsen FE. Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science (New York, N.Y.). 241: 701-3. PMID 2899909 DOI: 10.1126/Science.2899909  0.537
1987 Lewis SJ, Cincotta M, Verberne AJ, Jarrott B, Lodge D, Beart PM. Receptor autoradiography with [3H]L-glutamate reveals the presence and axonal transport of glutamate receptors in vagal afferent neurones of the rat. European Journal of Pharmacology. 144: 413-5. PMID 2894317 DOI: 10.1016/0014-2999(87)90399-2  0.397
1985 Lodge D, Johnston GA. Effect of ketamine on amino acid-evoked release of acetylcholine from rat cerebral cortex in vitro. Neuroscience Letters. 56: 371-5. PMID 3895050 DOI: 10.1016/0304-3940(85)90271-X  0.341
1977 Martin MR, Lodge D, Headley PM, Biscoe TJ. Pharmacological studies of facial motoneurones in the rat. European Journal of Pharmacology. 42: 291-8. PMID 856610 DOI: 10.1016/0014-2999(77)90296-5  0.371
1976 Biscoe TJ, Headley PM, Lodge D, Martin MR, Watkins JC. The sensitivity of rat spinal interneurones and renshaw cells to L-glutamate and L-aspartate. Experimental Brain Research. 26: 547-51. PMID 1010006 DOI: 10.1007/BF00238827  0.311
Show low-probability matches.